Anti-abortion advocates fume after FDA declines to immediately impose abortion pill limits

Reported by MS NOW. The paragraphs below are the opening of that article, reproduced word for word — not a summary, and not the whole piece.

A court-ordered status update said the agency does not plan to implement any restrictions while its review of the pill continues for several months.

Anti-abortion conservatives lashed out at the Trump administration after the Food and Drug Administration said it will not immediately limit access to the abortion pill mifepristone while it continues a review of the drug.

In a five-page, court-ordered status update filed Wednesday night, the government’s lawyers said officials will keep collecting data on mifepristone through December, and they expect to interpret the results and draft a report by March. The filing says the agency will not decide whether to impose changes to its drug safety program for mifepristone — which the FDA currently allows to be dispensed in-person or by mail for use through 10 weeks’ gestation — until after those steps are completed.

The update, which came as part of a lawsuit the state of Louisiana brought against the FDA last year seeking to restrict access to the pill, angered anti-abortion conservatives who have been pushing for an end to the telehealth prescribing and mailing of the pills.

Lila Rose, president of the group Live Action, called the government’s timeline “UNACCEPTABLE,” adding, “The FDA must pull the abortion pill from the market NOW.”

Marjorie Dannenfelser, president of SBA Pro-Life America, called the update “alarming” and said the agency is “trying to peddle fool’s gold.”